COBAS Amplicor: An automated PCR system for detection of C. trachomatis and N. gonorrhoeae

Expert Review of Molecular Diagnostics

Volumn 2, Issue 4, 2002, Pages 379-389

  Van Der Pol, Barbara ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chlamydia trachomatis; Neisseria gonorrhoeae; PCR; Sexually transmitted diseases; Sexually transmitted infections

Indexed keywords

AUTOANALYZER; CHLAMYDIA TRACHOMATIS; DISEASE TRANSMISSION; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; NEISSERIA GONORRHOEAE; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASE; ARTICLE; CHLAMYDIASIS; FORECASTING; GENETICS; GONORRHEA; INSTRUMENTATION; ISOLATION AND PURIFICATION; MOLECULAR PROBE;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FORECASTING; GONORRHEA; MOLECULAR PROBES; NEISSERIA GONORRHOEAE; POLYMERASE CHAIN REACTION;

EID: 0036020077     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996
2. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Review
3. Chlamydia trachomatis genital infections - United States 1995
4. Global prevalence and incidence estimates of selected curable STIs. Review
5. Evaluation of dry and wet transported intravaginal swabs in detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in female soldiers by PCR
6. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing but still substantial
7. Health and cost-benefits of chlamydia screening in young women. Review
8. Chlamydia screening - Yes but of whom, when, by whom and with what?
9. Control of Chlamydia trachomatis infections in female army recruits: Cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease
10. Screening women for Chlamydia trachomatis in family planning clinics: The cost-effectiveness of DNA amplification assays
11. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy
12. Epidemiology of genital Chlamydia trachomatis in England and Wales
13. Declining prevalence of chlamydial infection among adolescent girls
14. 1998 Guidelines for treatment of sexually transmitted diseases
15. Screening females for Chlamydia trachomatis (CT) In a large managed care organization (MCO). A new HEDIS measure
16. Population-level intervention to promote chlamydia screening. Moving toward implementation of chlamydia HEDIS 2000 measure
17. Evaluation of the Abbott LCx ligase chain reaction assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine and genital swab specimens from a sexually transmitted disease clinic population
18. Ability of commercial ligase chain reaction and PCR assays to diagnose Chlamydia trachomatis infections in men by testing first-void urine
19. The role of molecular diagnostics in the clinical microbiology laboratory
20. Evaluation of laboratory testing methods for Chlamydia trachomatis infection in the era of nucleic acid amplification
21. Urine specimens from pregnant and nonpregnant women inhibitory to amplification of Chlamydia trachomatis nucleic acid by PCR, ligase chain reaction and transcription-mediated amplification: Identification of urinary substances associated with inhibition and removal of inhibitory activity
22. Comparison of manual Amplicor PCR, COBAS Amplicor PCR and LCx assays for detection of Chlamydia trachomatis infection in women by using urine specimens
23. Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs and male urethral swabs
24. An internal control for routine diagnostic PCR: Design, properties and effect on clinical performance
25. Evaluation of COBAS AMPLICOR (Roche): Accuracy in detection of Chlamydia trachomatis and Neisseria gonorrhoeae by coamplification of endocervical specimens
26. Multicenter international work flow study of an automated polymerase chain reaction instrument
27. Performance characteristics of the Becton Dickinson ProbeTec System for direct detection of Chlamydia trachomatis and Neisseria gonorrhoeae in male and female urine specimens in comparison with the Roche COBAS System
28. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management
29. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification PCR assay
30. Comparison of Roche COBAS Amplicor and Abbott LCx for the rapid detection of Chlamydia trachomatis in specimens from high-risk patients
31. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis
32. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae
33. Determination of Chlamydia trachomatis prevalence in an asymptomatic screening population: Performances of the LCx and COBAS Amplicor tests with urine specimens
34. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture and three nucleic acid amplification tests
35. Comparison between the LCx Probe system and the COBAS AMPLICOR system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in patients attending a clinic for treatment of sexually transmitted diseases in Amsterdam, The Netherlands
36. Inhibition of PCR in genital and urine specimens submitted for Chlamydia trachomatis testing
37. Detection of PCR inhibitors in cervical specimens by using the AMPLICOR Chlamydia trachomatis assay
38. Comparison of three commercially available amplification assays, AMP CT, LCx and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine
39. Comparison of two commercially available nucleic acid amplification tests for the detection of Neisseria gonorrhoeae using female urine
40. Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB Nested PCR and 16s rRNA PCR
41. Enhancing the specificity of the COBAS AMPLICOR CT/NG test for Neisseria gonorrhoeae by retesting specimens with equivocal results
42. Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: A performance review with clinical and public health considerations
43. Reproducibility problems with the Abbott laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae
44. Reproducibility of three commercially available nucleic acid-based assays of detection of C. trachomatis and N. gonorrhoeae from urine
45. An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by β-globin gene amplification
46. Influence of endocervical specimen quality on PCR and direct fluorescent-antibody staining for detection of Chlamydia trachomatis infections
47. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens
48. Multicenter evaluation of the fully automated COBAS AMPLICOR PCR test for detection of Chlamydia trachomatis in urogenital specimens
49. Comparison of performances of two commercially available tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydla trachomatis infection
50. Comparison of a transcription-mediated amplification assay and polymerase chain reaction for detection of Chlamydia trachomatis in first-void urine
51. Detection of male genital infection with Chlamydia trachomatis and Neisseria gonorrhoeae using an automated multiplex PCR system (Cobas Amplicor)
52. Detection of Chlamydia trachomatis in symptomatic and asymptomatic populations with urogenital specimens by AMP CT (Gen-probe incorporated) compared to others commercially available amplification assays